Edition:
United States

Galapagos NV (GLPG.AS1)

GLPG.AS1 on Amsterdam Stock Exchange

64.84EUR
16 Jan 2017
Change (% chg)

€-0.64 (-0.98%)
Prev Close
€65.48
Open
€65.51
Day's High
€66.29
Day's Low
€64.75
Volume
171,740
Avg. Vol
--
52-wk High
--
52-wk Low
--

Latest Key Developments (Source: Significant Developments)

Galapagos says share capital increase arising from warrant exercises
Tuesday, 20 Jun 2017 08:24pm EDT 

June 20 (Reuters) - Galapagos Nv ::Announces a share capital increase arising from warrant exercises..Issued 52,030 new ordinary shares on 20 June 2017, for a total capital increase of 631,898.90 euros..  Full Article

Galapagos announces successful completion of Phase 1
Tuesday, 20 Jun 2017 01:55am EDT 

June 20 (Reuters) - Galapagos nv :GALAPAGOS' RESEARCH AND DEVELOPMENT UPDATE 2017: RAPIDLY ADVANCING OUR PRODUCT CANDIDATES.CYSTIC FIBROSIS: START OF REGULATORY PROCESS NEXT MONTH, PATIENT STUDY WITH FIRST TRIPLE COMBO EXPECTED TO BEGIN IN Q4 '17 IN EUROPE‍​.ON FILGOTINIB: DARWIN 3: IMPROVED ACTIVITY, CONSISTENT SAFETY PARAMETERS FOR FILGOTINIB; PH2 STUDIES INITIATED IN 6 NEW INDICATIONS.TOPLINE DATA FOR GLPG1690 IN IPF IN Q3 '17.OPENING OF US IND AND DOSING OF FIRST OSTEOARTHRITIS PATIENT IN PHASE 1B TRIAL WITH GLPG1972.CYSTIC FIBROSIS: SUCCESSFUL COMPLETION OF PH1 WITH THREE INDIVIDUAL COMBO COMPONENTS‍​.  Full Article

Galapagos Qtrly loss per share EUR 0.29
Thursday, 27 Apr 2017 04:00pm EDT 

April 27 (Reuters) - Galapagos NV ::Reg-Galapagos reports first quarter 2017 results.Q1 revenue rose 169 percent to eur 39.9 million.Reg-Galapagos reports first quarter 2017 results.End of Q1 cash eur 958.6 million.Qtrly loss per share eur 0.29.  Full Article

Galapagos announces closing of public offering of American Depositary Shares for gross proceeds of 363.9 million euros
Monday, 24 Apr 2017 03:32am EDT 

April 24 (Reuters) - Galapagos NV ::Announces on Friday the closing of public offering of 4,312,500 American Depositary Shares, at a price of $90.00 per American Depositary share, for gross proceeds of 363.9 million euros ($394.4 million).This includes the full exercise of the underwriters’ option to purchase additional American Depositary Shares.All of the American Depositary Shares were offered by Galapagos.  Full Article

Galapagos announces share capital increase
Monday, 24 Apr 2017 03:28am EDT 

April 24 (Reuters) - Galapagos NV ::Announces on Friday a share capital increase as a result of a public offering of American Depositary Shares.Total share capital currently amounts to 274,854,440.18 euros.  Full Article

Galapagos priced 3.75 mln new ordinary shares at $90 per ADS
Monday, 17 Apr 2017 10:09pm EDT 

April 17 (Reuters) - Galapagos Nv :Galapagos raises $338 million gross proceeds in a U.S. public offering.Priced its U.S. public offering totaling $338 million gross proceeds of 3.75 million new ordinary shares at $90 per ADS.  Full Article

Galapagos initiates Phase 1 study with novel CF potentiator GLPG3067
Wednesday, 22 Mar 2017 02:31am EDT 

Galapagos NV : Initiates Phase 1 study with novel CF potentiator GLPG3067 . Triggers a $7.5 million milestone payment from AbbVie . Third potentiator in growing portfolio of cystic fibrosis drug candidates . Aim of the phase 1 study is to evaluate the safety, tolerability and pharmacokinetics of oral single and multiple ascending doses of GLPG0367 . Safety and tolerability of the combination of GLPG3067 and GLPG2222 will also be evaluated. ."we plan to initiate multiple studies within our cf portfolio in the course of this year, as we get closer to our goal of initiating a patient evaluation of a triple combination therapy by mid-2017." - CSO.  Full Article

Galapagos announces two Phase 2 studies with filgotinib in small bowel and fistulizing Crohn's disease
Friday, 10 Mar 2017 01:30am EST 

Galapagos Nv : announces two new phase 2 studies investigating filgotinib in small bowel Crohn's disease as well as in fistulizing Crohn's disease .studies are being led by filgotinib collaboration partner Gilead Sciences.  Full Article

Galapagos expects expenses higher than 2017 milestones - conf call
Friday, 24 Feb 2017 09:00am EST 

Galapagos NV : Expects its expenses to be a little bit higher than milestones coming in in 2017 - conf call Further company coverage: [GLPG.AS] (Gdynia Newsroom) ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;)).  Full Article

Galapagos 2016 net result turns to profit of EUR 54.0 mln
Friday, 24 Feb 2017 03:49am EST 

Galapagos NV : 2016 revenues increased by 91.0 million euros ($96.41 million) to 151.6 million euros . 2016 operating loss reduced by 77.9 million euros to 11.5 euros million . 2016 net profit of 54.0 million euros, compared to a net loss of 118.4 million euros in 2015 . 2016 cash balance increased by 632.7 million euros to 980.9 million euros at year-end . Starts three Phase 3 studies with Filgotinib .Expects an operational use of cash of 135-155 million euros during 2017.  Full Article

BRIEF-Galapagos announces new phase 2 study with filgotinib

* NEW PHASE 2 STUDY WITH FILGOTINIB IN NON-INFECTIOUS UVEITIS‍​